A deeper understanding of how LKB1 restricts tumour formation, and the identification of the intestinal cell types most prone to transformation, are thus needed to allow the development of novel treatments for PJS, a disease for which there are presently no approved pharmaceutical strategies. This evidence concerns the gene STK11 and Peutz-Jeghers syndrome.